Neerav Shah, MD
Cardiovascular Disease · Wellington, FLNPI 1144212770
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.3%), other and speaking fees — rather than concentrated in one kind of arrangement. 56 manufacturers reported payments, led by Angiodynamics, Inc. at 32.3% of the total. Reporting peaked in 2024 at $35,750 and has fallen 84.7% since, to $5,480 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,085 payments — averaging $77.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$27K
- Cardiovascular Systems Inc.$12K
- Atricure, Inc.$6K
- Abbott$5K
- Shockwave Medical, Inc$4K
- Abiomed$3K
- plus $27K from 50 others
Across 701 payments — averaging $2848.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$977K
- Janssen Research & Development, LLC$564K
- Boehringer Ingelheim International GmbH$190K
- Novo Nordisk AS$178K
- Boehringer Ingelheim Pharma GmbH & Co.kg$62K
- Novartis$16K
- plus $11K from 3 others
What the payments were for
- Speaking & faculty fees$9,30011%
- Travel & lodging$7,9049%
- Food & beverage$39,72147%
- Education$990%
- Other$27,00032%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$27,000
- Coronary Orbital Atherectomy System$9,849
- SYNERGY ABLATION SYSTEM$3,516
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$3,217
- ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$2,944
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$2,730
- Impella$2,604
- Indigo System$1,718
- ATRICLIP LAA EXCLUSION SYSTEM$1,371
- WATCHMAN Access System$1,339
- Xience V coronary stent system$1,069
- Barostim Neo System$1,038
- XARELTO$638
- (BR5) Peripheral IVUS$529
- Repatha$486
- ESPRIT$452
- Zilver PTX$446
- Resolute$406
- MitraClip$400
- LINQ II$364
How this compares
$84,024 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 355 | $331,306 |
| EntrestoSacubitril/Valsartan | 124 | $144,720 |
| XareltoRivaroxaban | 109 | $111,743 |
| JardianceEmpagliflozin | 58 | $49,773 |
| Repatha SureclickEvolocumab | 42 | $45,029 |
| BrilintaTicagrelor | 40 | $37,979 |
| Praluent PenAlirocumab | 30 | $24,633 |
| VascepaIcosapent Ethyl | 18 | $17,374 |
| Repatha SyringeEvolocumab | 17 | $14,848 |
| Metoprolol Succinate | 560 | $7,587 |
| Ranolazine ErRanolazine | 70 | $5,581 |
| Rosuvastatin Calcium | 262 | $3,564 |
| ClopidogrelClopidogrel Bisulfate | 317 | $3,211 |
| Atorvastatin Calcium | 252 | $2,705 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 63 | $2,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $158 | $331,306355 claims |
| NovartisEntresto | $2,644 | $144,720124 claims |
| Johnson & JohnsonXarelto | $1,960 | $111,743109 claims |
| Boehringer IngelheimJardiance | $1,412 | $49,77358 claims |
| AstraZenecaBrilinta | $573 | $37,97940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Wellington
- Duccio BaldariWellington$157K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.